01 1Gowling Lafleur Henderson LLP
02 1Gowling WLG (Canada) LLP
01 12153692
02 12515444
01 2Natalizumab
01 2Solution
01 12014-01-07
02 12024-02-09
Patent Expiration Date : 2014-01-07
Date Granted : 2011-11-08
Brand Name : TYSABRI
Patent Number : 2153692
Filing Date : 1994-01-07
Strength per Unit : 300mg / 15 mL
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Intravenous Infusion
Patent Expiration Date : 2014-01-07
Date Granted : 2011-11-08
Patent Expiration Date : 2024-02-09
Date Granted : 2014-04-01
Brand Name : TYSABRI
Patent Number : 2515444
Filing Date : 2004-02-09
Strength per Unit : 300mg / 15 mL
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Intravenous Infusion
Patent Expiration Date : 2024-02-09
Date Granted : 2014-04-01
